Movatterモバイル変換

[0]ホーム

Jump to content

Bentracimab

Add links

From Wikipedia, the free encyclopedia

Medication

"REVERSE-IT" redirects here. For the Himiko Kikuchi album, seeHimiko Kikuchi.

Pharmaceutical compound

Bentracimab
Monoclonal antibody
Type	Fab fragment
Source	Human
Target	Ticagrelor, AR-C124910XX (theactive metabolite)^[1]
Clinical data
Other names	PB2452, MEDI2452
Routes of administration	Intravenous infusion
ATC code	None
Legal status
Legal status	Investigational
Identifiers
CAS Number	2260568-31-6
PubChem SID	405226665
DrugBank	DB16659
UNII	1TBM83QR9S
KEGG	D11799
Chemical and physical data
Formula	C₂₀₉₅H₃₂₄₀N₅₆₀O₆₇₄S₁₂
Molar mass	47440.93 g·mol⁻¹

Bentracimab is amonoclonal antibody medication which has been shown in phase one and twoclinical trials to function as a reversal agent for theanti–blood clotting drug ticagrelor (which acts as aP2Y₁₂ inhibitor and is sold under the brand name Brilinta among others).^[2] It is under investigation for use in major, life-threatening bleeding in patients being treated with ticagrelor.^[3]^[4] It is not commercially available.

References

[edit]

^"Specialist Pharmacy Service: Bentracimab".National Health Service. 10 January 2021.
^"EU patients enrolled in REVERSE-IT trial of bentracimab for reversal of antiplatelet effects of ticagrelor".Cardiovascular News. 2021-01-29.
^Clinical trial numberNCT04286438 for "A Phase 3, Multicenter, Open-Label, Single-Arm Study of Bentracimab (PB2452) in Ticagrelor-Treated Patients With Uncontrolled Major or Life-Threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure (REVERSE-IT Trial)" atClinicalTrials.gov
^Makhdoum A, Dhingra NK, Kirubaharan A, Eikelboom R, Luc J, Dagher O, et al. (August 2021)."Ticagrelor use and practice patterns among Canadian cardiac surgeons".Journal of Cardiac Surgery.36 (8):2793–2801.doi:10.1111/jocs.15636.PMID 34028081.

Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems

Bone

Human	Burosumab Denosumab
Humanized	Blosozumab^† Romosozumab

Musculoskeletal

Human	Stamulumab^†

Circulatory

Human	Abelacimab Alirocumab Ascrinvacumab^§ Bentracimab^† Enoticumab Evinacumab Evolocumab Icrucumab Inclacumab Marstacimab Nesvacumab Orticumab Ramucirumab Rinucumab
Mouse	Biciromab^‡ Imciromab^‡
Chimeric	Abciximab Volociximab
Humanized	Alacizumab pegol Bevacizumab/Ranibizumab Bococizumab Brolucizumab Caplacizumab Concizumab Demcizumab Emicizumab Etaracizumab Faricimab Idarucizumab Ralpancizumab Tadocizumab Vanucizumab

Neurologic

Human	Anti-amyloid drugs Aducanumab^‡ Donanemab Gantenerumab^† Lecanemab Erenumab Fasinumab^† Fulranumab Opicinumab
Humanized	Bapineuzumab^† Crenezumab^† Eptinezumab Fremanezumab Galcanezumab Ozanezumab Ponezumab Refanezumab Semorinemab Solanezumab Tanezumab^†

Angiogenesis inhibitor

Humanized	Ranibizumab

Growth factor

Human	Bimagrumab Trevogrumab
Humanized	Domagrozumab Landogrozumab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Thismonoclonal antibody–related article is astub. You can help Wikipedia byexpanding it.

Thisdrug article relating to theblood andblood forming organs is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Bentracimab&oldid=1136152398"

Categories:

Hidden categories:

[8]ページ先頭

Movatterモバイル変換

See also

References